Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Inclusion Criteria: * Histologically confirmed unresectable malignant melanoma * Radiographic or clinical evidence of metastatic disease * Measurable disease with ≥ 1 lesion whose longest diameter can be measured as ≥ 2.0 cm by CT or MRI scans or ≥ 1.0 cm by spiral CT scan * Disease that is measurable by physical examination only is not allowed * No known intraluminal metastatic lesion(s) with suspected bleeding * No brain metastases by MRI or CT scan * ECOG performance status 0-2 * Life expectancy \> 12 weeks * WBC ≥ 3,000/μL * Hemoglobin ≥ 9 g/dL * Absolute neutrophil count ≥ 1,500/μL * Platelets ≥ 100,000/μL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Creatinine ≤ 1.5 times ULN * Serum troponin normal * Urine protein ≤ 1+ (≤ 30 mg/dL) on 2 consecutive dipstick or other urine assessments taken ≥ 1 week apart * QTc interval \< 480 msec * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No significant ECG abnormalities (e.g., frequent ventricular ectopy, evidence of ongoing myocardial ischemia) * No serious nonhealing wound, ulcer, or bone fracture * No history of abdominal fistula, gastrointestinal perforation, active diverticulitis, intra-abdominal abscess, or gastrointestinal tract bleeding within the past 28 days * No history of myocardial infarction, cardiac arrhythmia within the past 6 months * No NYHA class III-IV heart failure * Patients with a history of class II heart failure and who are asymptomatic on treatment may be eligible * No history of bleeding disorder, including hemophilia, disseminated intravascular coagulation, or any other abnormality of coagulation potentially predisposing patients to bleeding * No uncontrolled infection * No evidence of active bleeding or bleeding diathesis * No hemoptysis within 6 weeks of first dose of study drug * No active peptic ulcer disease * No inflammatory bowel disease * No ulcerative colitis or other gastrointestinal conditions with increased risk of perforation * No history of cerebrovascular accident, including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months * Patients with recent deep vein thrombosis who have been treated with therapeutic anticoagulating agents within the past 6 weeks are eligible * No known endobronchial lesions or involvement of large pulmonary vessels by tumor * No current active hepatic or biliary disease, except Gilbert syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease * No uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 140 mm Hg and diastolic BP \> 90 mm Hg) * No condition that impairs ability to swallow and retain pazopanib hydrochloride (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) * No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would or might reasonably be expected to limit compliance with study requirements * No admission for unstable angina, cardiac angioplasty, or stenting within the past 6 months * More than 6 weeks since prior major surgery * More than 4 weeks since prior and no concurrent radiotherapy * At least 14 days or 5 half-lives and no concurrent CYP interactive medications * No prior radiotherapy to ≥ 25% of bone marrow * No prior therapy with a VEGFR tyrosine-kinase inhibitor * No concurrent antiretroviral therapy for HIV-positive patients * No concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of pazopanib hydrochloride * No concurrent chemotherapy * No other concurrent investigational agents * No other concurrent anticancer agents or therapies * No concurrent medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes